Abstract
The aim of this study was to compare two formulations of film-coated pellets containing clarithromycin after single oral dose study in healthy male volunteers. Two formulations with different coating polymers were prepared: formulation-1 (F-1) was prepared by incorporating three kinds of pH-dependent gradient-release coated pellets into capsules and formulation-2 (F-2) was prepared by coated with an insoluble semiosmotic film. Release profiles of film-coated pellets were evaluated using paddle method under different conditions. Pharmacokinetic profiles of these formulations were obtained in three healthy male volunteers and compared to commercially available immediate release (IR) tablets. The relative bioavailability based on the AUC0–24 h was found to be 96.2% and 58.7% for F-1 and F-2 compared with IR, and the Tmax was delayed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amidon, G. L., Lennemas, H., Shah, V. P., and Crison, J. R., A theoretical basis for a biopharmaceutical drug classification: the correlation ofin vitro drug product dissolution andin vivo bioavailability.Pharm. Res., 12, 413–420 (1995).
Amighi, K., Timmermans, J., Puigadevall, J., Baltes, E., and Moës, A. J., Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drugrelated problems. IIn vitro development and eveluation.Drug Dev. Ind. Pharm., 24, 509–515 (1998).
Arimori, K., Miyamoto, S., Fukuda, K., Nakamura, C., and Nakano, M., Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin.Biopharm. Drug Dispos., 19, 433–438 (1998).
Bodmeier, R., Tableting of coated pellets.Eur. J. Pharm. Biopharm., 43, 1–8 (1997).
Chu, S. Y., Deaton, R., and Cavanaugh J., Absolute bioavailability of clarithromycin after oral administration in humans.Antimicrob. Agents Chemother., 36, 1147–1150 (1992a).
Chu, S. Y., Granneman, G. R., Pichotta, P. J., Decout, J. P., Girault, J., and Fourtilan, J. B., Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.J. Clin. Pharmacol., 33, 480–485 (1993).
Chu, S. Y., Park, Y., Locke, C., Wilson, D. S., and Cavanaugh, J. C., Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial.J. Clin. Pharmacol., 32, 32–36 (1992b).
Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell T. L., Schmaltz, S. P., Barnett, J. L., and Jarvenpaa, K. M., Upper gastrointestinal (GI) pH in young, healthy men and women.Pharm. Res., 7, 756–761 (1990).
Erah, P. O., Barrett, D. A., and Shaw, P. N. Ion-pair high-performance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice.J. Chromatogr. B., 682, 73–78 (1996).
Grubel, P. and Cave, D. R., Factors affecting solubility and penetration of clarithromycin through gastric mucus.Alim. Pharmacol. Ther., 12, 569–576 (1998).
Guay, D. R., Gustavson, L. E., Devcich, K. J., Zhang, J., Cao, G., and Olson, C. A., Pharmacokinetics and tolerability of extended-release clarithromycin.Clin. Ther., 23, 566–577 (2001).
Nakagawa, Y., Itai, S., Yoshida, T., and Nagai, T., Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparision with erythromycin.Chem. Pharm. Bull., 40, 725–728 (1992).
Rodvold, K. A., Clinical pharmacokinetics of clatrithromycin.Clin. Pharmacokinet., 37, 385–398 (1999).
Sathe, P. M., Tsong, Y., and Shah V. P.,In-vitro dissolution profile comparision: statistics and analysis, model dependent approch.Pharm. Res., 13, 1799–1803 (1996).
Sousa, J. J., Sousa, A., Moura, M. J., Podczeck, F., and Newton, J. M., The influence of core materials and film coating on the drug release from coated pellets.Int. J. Pharm., 233, 111–122 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Xr., Chen, Xy., Hu, LD. et al. Evaluation ofin-vitro dissolution andin-vivo absorption for two different film-coated pellets of clarithromycin. Arch Pharm Res 28, 977–982 (2005). https://doi.org/10.1007/BF02973886
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02973886